Kidney Cancer Articles | Page 2

Immunotherapy Combinations on the Rise for RCC
The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.
Agarwal Recaps Advancements in Newly Diagnosed RCC
Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC. 
Optimizing Adjuvant Therapy in Renal Cell Carcinoma
Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.
Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC
Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.
Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC
The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.
FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.
Cabozantinib RCC Benefit Highlighted as Frontline Approval Approaches
Cabozantinib (Cabometyx) remains to be the sole oral drug to meet 3 clinical trial endpoints of progression-free survival, overall survival, and overall response rate in patients with advanced RCC.
Pal Shares Insight on Abundance of Options in GU Malignancies
Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.
NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
Publication Bottom Border
Border Publication